Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Part B Shift To Discourage Prescribing Of Costly New 340 Drugs Weighed By MedPAC

Executive Summary

Linking clinical superiority to payments is another recommendations on Medicare reimbursement for separately payable drugs in the hospital outpatient prospective payment system under consideration by the Medicare Payment Advisory Commission.

You may also be interested in...



Second-Guessing FDA? Sage Zulresso Denied Add-On Status In Medicare

Medicare’s doubts about trial design for Sage’s postpartum depression therapy suggests even ‘breakthrough’-designated products can struggle with the ‘substantial clinical improvement’ standard for NTAP status. Denial of enhanced payment for Zulresso ends a long winning streak by innovators.

Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?

PhRMA is stepping up its advocacy for 340B reform, noting recent reduction in Medicare payments for 340B is encouraging in that it indicates Administration may be open to further change.

Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’

The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144026

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel